Ms Kim Hunter. Clinical Nurse Coordinator Immunisation Population Health Waikato District Health Board
|
|
- Earl Cain
- 5 years ago
- Views:
Transcription
1 Ms Kim Hunter Clinical Nurse Coordinator Immunisation Population Health Waikato District Health Board 11:30-12:00 A Hitchhiker's Guide to Vaccine Preventable Disease
2 Hitchhikers Guide to Vaccines and Preventable Disease Kim Hunter Medical Science Liaison - Vaccines
3 Presentation Overview Varicella vaccination key points to note Pertussis vaccination strategies and goals
4 Varicella virus the causative agent Varicella zoster virus (VZV) Primary infection with VZV results in: varicella (chickenpox) latency Reactivation results in: herpes zoster (HZ / shingles) 1. Heininger U et al. Lancet 2006;368: Electron micrograph of VZV courtesy of Professor Anne Gershon
5 Varicella causes substantial illness in NZ Figure 21.1: Hospitalisations for varicella, rates continue to rise Every year in NZ ~60,000 people get chickenpox; several hundred are admitted to hospital. 1 Maori and Pacific Island are 3 and 4 times more likely to be hospitalised than European children 2 1. Ministry of Health Draft Immunisation Handbook wording; Personal correspondence. Wellington: Ministry of Health 2. Wen SC et al. J Paediatr Child Health 2015;51: Image by
6
7 Serious financial and social burden associated with varicella Mild, uncomplicated varicella can last for up to two weeks with: 1-3 Substantial medical costs from treating the disease and its complications Societal costs due to absence from work Parents can suffer stress, sleep deprivation, family breakdown and loss of income 4 1. Heininger U et al. Lancet 2006;368: Banz K et al. Eur J Health Econ 2004;5: Coupeville L et al. Value Health 2005;8: Soarez PC et al. Cad Saude Publica 2009;25(3):S
8 Varilrix live attenuated varicella vaccine 1 10 vials of lyophilised vaccine with 10 syringes of diluent (reconstitute) 1 dose at 15 months: 2 o Those born on or after 1 st April dose for those turning 11 yrs old on or after 1 st July 2017, if: o Unvaccinated o No history of varicella 2 Given alongside MMR, Hib, and PCV 2 High risk criteria will remain the same 2 1. GlaxoSmithKline New Zealand. Varilrix Data Sheet. GSK NZ;2016. Available at Accessed August Pharmaceutical Management Agency New Zealand. Changes to the National Immunisation Schedule. Available at Accessed February 2017
9 Varilrix is a well established vaccine Varilrix has been available for over 30 years and is currently licensed in over 96 countries 1 Used in funded programmes in Australia, the United States, and Germany 1 Available in NZ since 1996 and has been funded for the high risk population since GlaxoSmithKline New Zealand Data on file Pharmaceutical Management Agency New Zealand. Changes to the National Immunisation Schedule. Available at Accessed August 2016.
10 One dose is highly effective at preventing moderate to severe cases resulting in fewer hospitalisations 1 One dose: % effective in preventing moderate to severe cases of chickenpox 57-72% effective in preventing all chickenpox Two doses: % effective in preventing moderate to severe cases of chickenpox 92-97% effective in preventing all chickenpox Breakthrough disease: 2 Can occur following a single dose Disease is generally milder than an unvaccinated child resulting in fewer skin lesions 1. GlaxoSmithKline New Zealand. Varilrix Data Sheet. GSK NZ;2016. Available at Accessed August Seward JF et al. JAMA 2004;292:704-8.
11 1. Heywood AE et al. Bull World Health Organ 2014;92(8): Quian J et al. Arch Dis Child 2008;93: Guris D et al. J Infect Dis 2008;197: S Marin M et al. J Infect Dis 2008;197:S94-S Marin M et al. Pediatrics 2008;22:e WHO. Position Paper Varicella and Zoster. [Online] Accessed June SAGE Working Group on Varicella and Herpes Zoster Vaccines. Background Paper on Varicella Vaccine. April Accessed June High coverage is crucial to effectively protect with a one-dose schedule 1 Rapid, high (> 80%) and sustained coverage with a one dose varicella universal mass vaccination (UMV) schedule is critical for: Herd protection 1 Reducing the risk of transmission to others 2-5 Avoiding an upward age shift of varicella disease which is more severe in adults 1,6,7
12 Duration of Protection When chickenpox continues to circulate, giving opportunities for regular boosting of vaccine-induced immunity, protection lasts for at least 20 years. 1 One dose 2 Unknown whether waning immunity after one dose is evident Breakthrough disease does not become more severe with age Reductions in circulating disease may reduce duration of protection Two doses 3 Appears to be very long term for most people immunised It is not known if it is lifelong 1. Takahashi, M. Paediatri Drugs. 2001;3: SAGE WHO; 2014 Available from: 3. IMAC. Chickenpox factsheet. Accessed July 2016.
13 Herd effect seen in Australia following varicella universal vaccination programme Following introduction of 1-dose universal vaccination programme in Australia: Vaccine administered at 18 months of age: 60% decline in hospitalisation rates for infants aged <1 year, demonstrating that unvaccinated infants also benefit from routine childhood vaccination Varicella hospitalisations decreased in all age groups 1.Heywood AE et al. Bull World Health Organ 2014;92(8):
14 14 1.Heywood AE et al. Bull World Health Organ 2014;92(8):
15 No increase in Herpes Zoster (HZ) seen in the USA and Australia Concerns regarding an increased HZ rate associated with varicella vaccination programmes appear to be unfounded 1 US experience 1 No difference in the slope of increase in HZ incidence rate before and after the introduction of varicella vaccine Australian experience 2 HZ hospitalisations rate did not increase over time Despite high varicella vaccination coverage in Australia for almost five years 1. WHO. Position Paper Varicella and Zoster. [Online] Accessed June Heywood AE et al. Bull World Health Organ 2014;92(8):
16 Varicella high-risk funding criteria unchanged A max of 2-doses of Varilrix for the following people: For non-immune patients: with chronic liver disease who may in future be candidates for transplantation; or with deteriorating renal function before transplantation; or prior to solid organ transplant; or prior to any elective immunosuppression* For patients at least 2 years after bone marrow transplantation, on advice of their specialist For patients at least 6 months after completion of chemotherapy, on advice of their specialist Ministry of Health Immunisation Handbook 2017; Wellington: Ministry of Health. Available at Accessed July 2017.
17 Varicella high-risk funding criteria For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist Individuals with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella For household contacts (with no history of varicella) of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise For household contacts (with no history of varicella) of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise Ministry of Health Immunisation Handbook 2017; Wellington: Ministry of Health. Available at Accessed July 2017.
18 Varilrix prescribing information Varilrix (live attenuated varicella vaccine) is available as an injection, 0.5mL per dose. Varilrix is a private-purchase prescription medicine for immunisation and prophylaxis against varicella (chickenpox) in adults and children older than 9 months. A prescription charge will apply. Varilrix is also funded for certain high-risk groups and their contacts. From July 2017, one dose of Varilrix will be fully funded on the National Immunisation Schedule at 15 months of age and for previously unvaccinated children turning 11 years old who have not previously had a varicella infection. Children aged 13 years and older need two doses with an interval between doses of at least 6 weeks. Two doses at least 6 weeks apart are also recommended for children aged between 9 months and 12 years, to provide optimal immune responses against varicella virus. Contraindications: acute severe febrile illness, lack of cellular immunity (e.g. leukaemia, lymphoma, HIV infection, or immunosuppressive therapy), known systemic hypersensitivity to neomycin or any component of the vaccine, or pregnancy. Pregnancy should also be avoided for 3 months after vaccination. Precautions: do not administer intradermally or intravenously. Ensure medical treatment is readily available in case of fainting or rare anaphylactic reaction following administration. Use caution in patients with serious chronic diseases (such as chronic renal failure, autoimmune diseases, collagen diseases, or severe bronchial asthma). Avoid salicylates for 6 weeks after vaccination. Vaccination should be delayed for at least 3 months after a patient has received immunoglobulins or a blood transfusion. If a measles vaccine is not given at the same time as Varilrix, it should be delayed by at least 1 month. Alcohol and other disinfecting agents must be allowed to evaporate from the skin before injection of the vaccine. Common side effects include mild rash; pain, redness and swelling at the injection site; and small numbers of papulo-vesicular eruptions. Uncommon side effects include fever, headache, cough, vomiting, lymphadenopathy, and arthralgia. Before prescribing Varilrix, please review the full Data Sheet at Varilrix is a registered trade mark of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on
19 Pertussis vaccination - strategies and goals
20 Pertussis is highly contagious It is estimated that in an immune-naïve population, 1 primary case of pertussis can cause approximately 12 to 17 new cases 1,2 The reproductive values for pertussis are close to measles, and higher than mumps, polio, rubella or smallpox 2 1. Schellekens J et al. Pediatr Infect Dis J 2005;24:S19 S24; 2. Fine PE: Epidemiol Rev 1993;15:
21 Higher numbers of pertussis cases reported to date in 2017 versus Accessed August 2017
22 The highest rates are among the <1 year and 1 4 years age groups (43.9 and 35.9 per 100,000) ESR Pertussis Report: Acessed August 2017
23 Pertussis containing vaccines spaced effectively across immunisation schedule 23
24 EPIC study shows Infanrix hexa is highly effective in preventing pertussis in NZ infants Radke et al. / Vaccine 35 (2017) vac 24
25 Percentage of total source contacts with pertussis Mothers are the most common source of pertussis infection 60 Sources of infant pertussis cases by contact category (%) Any parent Mother Father Sibling Grandparent Other Pooled data from a maximum of 7 studies which included case infants less than 6 months old Data derived from Wiley KE et al. Vaccine 2013;31:
26 Immunisation strategies are needed to protect the most vulnerable Strategies proposed include: Maternal immunisation: targeting the most common source of infant infections 1 with the potential to provide protection to the foetus and newborn infant 2 1. Wiley KE et al. Vaccine 2013; 31: ; 2. Chu HY et al. Clin Infect Dis 2014; 59: ; 3. Zepp F et al. Lancet Infect Dis 2011; 11:
27 Immunisation strategies are needed to protect the most vulnerable Strategies proposed include: Maternal Cocooning: immunisation: immunising all close targeting contacts of the most common vulnerable source infantsof infant infections 1 with the potential to provide protection to the foetus and newborn infant 2 1. Wiley KE et al. Vaccine 2013; 31: ; 2. Chu HY et al. Clin Infect Dis 2014; 59: ; 3. Zepp F et al. Lancet Infect Dis 2011; 11:
28 Immunisation strategies are needed to protect the most vulnerable Strategies proposed : include: Booster Maternal Cocooning: immunisation of immunisation: immunising older children, all close targeting contacts adolescents of the and most common vulnerable adults with source infants the of infant overall infections aim of 1 with the reducing potential morbidity to in provide target populations protection to the and foetus increasing and herd newborn protectioninfant Wiley KE et al. Vaccine 2013; 31: ; 2. Chu HY et al. Clin Infect Dis 2014; 59: ; 3. Zepp F et al. Lancet Infect Dis 2011; 11:
29 NZ Immunisation Handbook 2017 Pertussis Recommendations The goal of the pertussis immunisation programme is to protect those most at risk of developing severe disease, that it, infants in the first year of life. 1 Two key strategies for reducing the burden of disease in infants are: 1. Vaccination during pregnancy 28 to 38 weeks gestation, every pregnancy, to protect the mother and so antibodies can pass to the fetus 2. More complete and timely delivery of the current infant immunisation schedule 1 Post partum maternal vaccination will reduce the risk of the mother infecting her baby but does not have the added benefit of providing passive antibodies 1 NZ recommendations in line with both the Advisory Committee on Immunisation Practices (ACIP) 2012 and WHO 2015 Key Position 2,3 Ministry of Health Immunisation Handbook 2017; Wellington: Ministry of Health. Available at Accessed July CDC. MMWR 2013; 62(7): World Health Organization. Pertussis vaccines: WHO position paper August Wkly Epidemiol Rec 2015;90:433 60
30 The Immunisation Handbook recommends a pertussis booster for people in contact with infants - not funded Ministry of Health Immunisation Handbook 2017; Wellington: Ministry of Health. Available at Accessed July 2017.
31 Increase vaccination Barriers and enablers for Tdap vaccine uptake during pregnancy/post-partum Predictors/enablers Vaccination against influenza during pregnancy 1,10 Incorporating maternal immunisation into routine obstetric care 2 Younger age of mothers 3 In-hospital vaccine ordering procedures 4 Deployment of clinical decision support systems 5 Barriers/inhibiters Lack of recommendation from HCP 6,7 Lack of knowledge of risk and consequences of neonatal pertussis infection 8 Lack of trust or confidence in the vaccine 9 Concerns about safety 8 Delivering pre-term 1 Prevent vaccination 1. Goldfarb IT, et al. Am J Obstet Gynecol 2014; 211:299.e Webb H, et al. Hum Vaccin Immunother 2014;10(4): Donnan EJ, et al. BMC Public Health 2013; 13: Yeh S, et al. Am J Obstet Gynecol 2014; 210:237.e1e Trick WE, et al. Obstet Gynecol 2010; 116: Urwyler P, et al. BMC Infect Dis 2014; 14: Wiley KE, et al. Vaccine 2013; 31: Moniz MH, et al. Hum Vaccin Immunother 2014;10: Cheng PJ, et al. Vaccine 2010; 28: Bodeker B, 31
32 Infant outcomes after exposure to Boostrix in pregnancy Objective: Collecting information to evaluate the safety of Boostrix for infants exposed during pregnancy A prospective observational study in New Zealand. 470 women who had received Boostrix during pregnancy were recruited. Infants were followed for 6 and 12 months after birth. Follow up data was obtained from 403 women on 408 infants (403 singleton infants, 6 sets of twins and one stillbirth). There were no significant differences in birth weight, gestational age at birth, congenital anomalies, or infant growth as compared to baseline population data. Walls T, Graham P, Petousis-Harris H, et al.bmj Open 2016;6:e doi: / bmjopen
33 Safety outcomes after exposure to Boostrix in pregnancy Objective: Actively recruit and follow pregnant women receiving a dose of Boostrix for 4 weeks after vaccination. A prospective observational study conducted in two NZ regions. 793 women in their 28th 38th week of pregnancy, recruited from primary care and antenatal clinics at the time of Boostrix administration. Outcomes measured were injection site reactions, systemic symptoms and serious adverse events (SAEs) Vaccination with Boostrix in pregnant women was well tolerated with no SAE likely to be caused by the vaccine. Petousis-Harris H, Walls T, Watson D, et al.bmj Open 2016;6:e doi: /bmjopen
34 1. PHARMAC. Changes to the National Immunisation Schedule. Available at Accessed August GlaxoSmithKline New Zealand. Boostrix Data Sheet. GSK NZ; Available at Accessed January Ministry of Health Immunisation Handbook 2017; Wellington: Ministry of Health. Available at Accessed July 2017 Boostrix Diphtheria, Tetanus, Pertussis No change to NIS 1 No concerns with co-administration 2 Updated data sheet now included on NZ pregnant women study one of the first in the world 2 Recommendations for pregnant women is to have a dose with every pregnancy between 28 and 38 weeks gestation 1 Recommended but not funded for adults in contact with infants for work or household contacts 3
35 Boostrix prescribing information Boostrix (combined diphtheria-tetanus-acellular pertussis (dtpa or Tdap) vaccine) is available as an injection. A 0.5 ml dose contains not less than 2.5 LfU of diphtheria toxoid, not less than 5 LfU of tetanus toxoid, and three purified Bordetella pertussis antigens (8mcg of pertussis toxoid, 8 mcg of filamentous haemagglutinin, and 2.5 mcg of 69 kda outer membrane protein). Boostrix is government funded for 11 year olds as part of the national immunisation schedule, and for pregnant women between 28 and 38 weeks gestation. (Category B1). It is also available as a private-purchase prescription medicine for booster vaccination against diphtheria, tetanus, and pertussis in individuals aged 4 years and older a prescription charge will apply. A trained pharmacist can also administer Boostrix to a person aged 18 years and older. Safety data where Boostrix was administered to pregnant women during the third trimester indicate no vaccine related adverse effect on pregnancy or on the health of the foetus/newborn child. Boostrix may be used during pregnancy when the possible advantages outweigh the possible risks for the foetus. Contraindications: known hypersensitivity to any component of the vaccine, encephalopathy after previous pertussis vaccination, or transient thrombocytopenia or neurological complications after previous vaccination against diphtheria and/or tetanus. Precautions: do not administer intravenously; ensure medical treatment is readily available in case of rare anaphylactic reaction following administration. Common side effects include fever, malaise, fatigue, headache, irritability, loss of appetite, vomiting, diarrhoea, and local reactions such as pain, redness, bruising, itching, or swelling at the injection site. Before prescribing Boostrix, please review the full Data Sheet at Boostrix is a registered trade mark of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on
36 Infanrix hexa prescribing information Infanrix hexa (combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b vaccine) is available as an injection. This vaccine should be administered by deep intramuscular injection. Each 0.5 ml dose of the vaccine contains not less than 30 IU of diphtheria toxoid, 40 IU of tetanus toxoid, 25 mcg of pertussis toxoid, 25 mcg of filamentous haemagglutinin, 8 mcg of pertactin, and 10 mcg of recombinant HBsAg protein, all adsorbed on hydrated aluminium hydroxide. Each 0.5 ml dose also contains inactivated polio virus: 40 D-antigen units of type 1 (Mahoney), 8 D-antigen units of type 2 (MEF-1), and 32 D-antigen units of type 3 (Saukett). It also contains 10 mcg of adsorbed purified capsular polysaccharide of H. influenzae type b (Hib) polyribosylribitol phosphate, conjugated to mcg of tetanus toxoid. Infanrix hexa is funded on the National Immunisation Schedule. Contraindications: encephalopathy following previous pertussis vaccination, or transient thrombocytopenia or neurological complications following earlier immunisation against diphtheria and/or tetanus. Precautions: do not administer intravenously; ensure medical treatment is readily available in case of rare anaphylactic reaction following administration; review medical history for progressive neurological disorders or any instances of reactions to previous vaccinations with pertussis; High incidence of fever (> 39.5 C), increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed in infants receiving Infanrix hexa and Prevenar compared to infants receiving the hexavalent vaccine alone. Common side effects include malaise, fatigue, headache, fever, irritability, loss of appetite, vomiting, diarrhoea, and local reactions such as pain, redness and swelling at the injection site; very rarely reported reactions include allergic reactions including anaphylactoid reactions. Before prescribing Infanrix hexa, please review the full Data Sheet at Infanrix hexa is a registered trade mark of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. 11/08/
37 Register at health.gsk.nz for GSK vaccines information and resources 54
Ms Kim Hunter. Clinical Nurse Coordinator Immunisation Population Health Waikato District Health Board
Ms Kim Hunter Clinical Nurse Coordinator Immunisation Population Health Waikato District Health Board 16:30-17:30 WS #135: Vaccination Update - What's New? Hitchhikers Guide to Vaccines and Preventable
More informationWhooping cough. Dr Pam Jackson
Whooping cough Dr Pam Jackson History of pertussis in NZ From 1873 1944 3.9 yearly epidemics Introduced vaccine in 1945 From 1945 2004 3.5 yearly epidemics Implies no impact on pertussis outbreaks Epidemic
More informationimmunisation in New Zealand
This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were
More informationCLINICAL PHARMACOLOGY INFANRIX DTPa vaccine, induces antibodies against all vaccine components.
INFANRIX PRODUCT INFORMATION NAME OF THE MEDICINE Diphtheria-tetanus-acellular pertussis (DTPa) vaccine DESCRIPTION INFANRIX DTPa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus
More informationChanges to the National Immunisation Schedule
17 December 2013 Changes to the National Immunisation Schedule PHARMAC is pleased to announce decisions related to the National Immunisation Schedule (NIS) that will take effect from 1 July 2014. This
More informationBOOSTRIX QUALITATIVE AND QUANTITATIVE COMPOSITION PHARMACEUTICAL FORM CLINICAL PARTICULARS. Indications. Dosage and Administration
BOOSTRIX Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus
More informationImmunisation Subcommittee of PTAC Meeting held 10 February (minutes for web publishing)
Immunisation Subcommittee of PTAC Meeting held 10 February 2014 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationBOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv)
BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv) Section 7: Biological Product Information Standard #: 07.213 Created by: Province-wide Immunization
More informationBOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine
BOOSTRIX Combined diphtheria, tetanus, acellular pertussis vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus toxoid 1 Bordetella pertussis antigens
More informationInfanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine
Infanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION Infanrix TM contains diphtheria toxoid, tetanus toxoid and three purified
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET INFANRIX HEXA Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b powder and suspension
More informationVaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives. August 2014
Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives August 2014 Quality Education for a Healthier Scotland 1 Key Message There is a lot
More informationBOOSTRIX POLIO. 3. PHARMACEUTICAL FORM Suspension for injection.
BOOSTRIX POLIO 1. NAME OF THE MEDICINAL PRODUCT boostrix polio Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) 2. QUALITATIVE
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX 1. QUALITATIVE AND QUANTITATIVE COMPOSITION contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and 69 kilodalton
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory INFANRIX Diphtheria Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. 1. NAME OF THE MEDICINAL PRODUCT
More informationObjectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015
Childhood Immunization Risk of Non-Vaccinated Children Bertha P. Rojas, Pharm.D. PGY-1 Pharmacy Resident South Miami Hospital Objectives Understand the definition of herd immunity Identify vaccine-preventable
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pre-filled syringe: IPV-Boostrix suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component)
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory INFANRIX HEXA Diphtheria, tetanus, pertussis (acellular component), hepatitis B (rdna), poliomyelitis (inactivated) and
More informationImmunisation Subcommittee of PTAC Meeting held 28 October 2015
Immunisation Subcommittee of PTAC Meeting held 28 October 2015 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationBoostrix polio. 3. PHARMACEUTICAL FORM Suspension for injection. 4. CLINICAL PARTICULARS
Boostrix polio 1. NAME OF THE MEDICINAL PRODUCT boostrix polio Combined diphtheria, tetanus, acellular pertussis and enhanced inactivated polio vaccine. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION boostrix
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine NAME OF THE MEDICINE INFANRIX hexa Combined Diphtheria-Tetanus-acellular
More informationPertussis immunisation for pregnant women
Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis. Before the introduction
More informationEnhanced immunisation schedule Victoria
Children from March 2016 Age Disease Vaccine brand Birth Hepatitis B H-B-Vax-II Paediatric 2 months - from 6 weeks Diphtheria-tetanus-pertussis, poliomyelitis-hepatitis B- Reconstitute Site given Route
More informationVARILRIX Product Information 1(9)
VARILRIX Product Information 1(9) VARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated DESCRIPTION VARILRIX is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster
More informationVaccination against pertussis (whooping cough) an update for registered healthcare practitioners Questions and Answers
Vaccination against pertussis (whooping cough) an update for registered healthcare practitioners Questions and Answers April 2016 Health Protection Scotland is a division of NHS National Services Scotland.
More informationINFANRIX HEXA QUALITATIVE AND QUANTITATIVE COMPOSITION PHARMACEUTICAL FORM CLINICAL PARTICULARS. Indications
INFANRIX HEXA Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine NAME OF THE MEDICINE INFANRIX hexa Combined Diphtheria-Tetanus-acellular
More informationDecision to amend access criteria for some vaccines
3 July 2015 Decision to amend access criteria for some vaccines PHARMAC is pleased to announce the following changes to the funding access criteria for a number of vaccines. The changes in criteria follow
More informationINFANRIX-IPV Product Information 1(13) INFANRIX IPV
INFANRIX-IPV Product Information 1(13) INFANRIX IPV NAME OF THE DRUG INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX
More informationCHILDHOOD VACCINATION
EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,
More informationThe hexavalent DTaP/IPV/Hib/ HepB combination vaccine
The hexavalent DTaP/IPV/Hib/ HepB combination vaccine Greenwich Practice Nurse Forum Oct 17 th 2017 Introduction of a hexavalent infant vaccine From autumn 2017, all babies born on or after 1 August 2017
More informationWhat are the new active vaccine recommendations in the Canadian Immunization Guide?
154 CCDR 17 April 2014 Volume 40-8 https://doi.org/10.14745/ccdr.v40i08a03 1 What are the new active vaccine recommendations in the Canadian Immunization Guide? Warshawsky B 1 and Gemmill I 2 on behalf
More informationMaternal vaccination
Maternal vaccination (Gary) Edwin Reynolds Immunisation Advisory Centre (IMAC) 0.1FTE University of Auckland Medical Advisor / General Practitioner Vaccinology / Immunology General Practitioner 0.1FTE
More informationYear 7 immunisation. Parent Consent Form
Year 7 immunisation Boostrix an immunisation to boost your child's protection against tetanus, diphtheria and whooping cough (pertussis) Parent Consent Form Please sign and return the form to school. COOK
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationINFANRIX -penta Datasheet
INFANRIX -penta Datasheet NAME OF THE MEDICINE INFANRIX -penta Combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated polio vaccine. QUALITATIVE AND QUANTITATIVE COMPOSITION INFANRIX
More informationTWINRIX GlaxoSmithKline
TWINRIX GlaxoSmithKline 1. Name of medicinal product Twinrix 2. Qualitative and quantitative composition Twinrix is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated
More informationInfanrix Hexa. Copyright , MIMS Australia Page 1 of 5
Infanrix Hexa MIMS Abbreviated Prescribing Information Diphtheria toxoid; haemophilus influenzae vaccine; hepatitis B vaccine; pertussis vaccine; poliomyelitis vaccine; tetanus toxoid GlaxoSmithKline Australia
More informationBOOSTRIX PRODUCT INFORMATION
BOOSTRIX PRODUCT INFORMATION NAME OF THE MEDICINE Combined diphtheria-tetanus-acellular pertussis (dtpa) vaccine DESCRIPTION BOOSTRIX dtpa vaccine is a sterile suspension which contains diphtheria toxoid,
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV) Section 7: Biological Product Information Standard #: 07.212 Created by: Province-wide Immunization Program Standards
More informationHIBERIX PRODUCT INFORMATION
HIBERIX PRODUCT INFORMATION NAME OF THE MEDICINE HIBERIX Haemophilus influenzae type b (Hib) vaccine DESCRIPTION Powder and diluent for solution for injection. After reconstitution, 1 dose (0.5 ml) contains:
More informationINFANRIX IPV PRODUCT INFORMATION
INFANRIX IPV PRODUCT INFORMATION NAME OF THE MEDICINE INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX IPV vaccine
More informationsanofi pasteur 352 Hexaxim New Zealand Data Sheet V2.0 DATA SHEET
DATA SHEET NAME OF THE MEDICINE HEXAXIM DTPa-hepB-IPV-Hib Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationBOOSTRIX -IPV PRODUCT INFORMATION. BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine.
BOOSTRIX -IPV PRODUCT INFORMATION NAME OF THE MEDICINE BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine. DESCRIPTION BOOSTRIX-IPV is a sterile
More informationINFANRIX HEXA QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX HEXA Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationBOOSTRIX -IPV. BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine.
BOOSTRIX-IPV Product Information 1(16) BOOSTRIX -IPV NAME OF THE DRUG BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine. DESCRIPTION BOOSTRIX-IPV
More informationImmunisation Subcommittee of PTAC Meeting held 23 April (minutes for web publishing)
Immunisation Subcommittee of PTAC Meeting held 23 April 2013 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationIf official recommendations call for additional doses of measles, mumps, rubella and/or varicella, Priorix-Tetra can be used for these doses.
Page 1 of 7 INFORMATION FOR HEALTH PROFESSIONALS Home Consumers Health Professionals Regulatory Other Hot Topics Search PRIORIX-TETRA Live attenuated measles, mumps, rubella and varicella vaccine Presentation
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Product Information 1(12) INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine DESCRIPTION INFANRIX hexa
More informationPentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
More informationSUMMARY OF PRODUCT CHARACTERISTICS. INFANRIX-IPV+Hib powder and suspension for suspension for injection
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT INFANRIX-IPV+Hib powder and suspension for suspension for injection Diphtheria (D), tetanus (T), pertussis (acellular component) (Pa),
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for registered healthcare practitioners about the introduction of the hexavalent vaccine into the routine infant immunisation programme
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationUpdated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010
Updated WHO position paper on pertussis vaccines Geneva, Switzerland October 2010 Introduction Replaces the position paper on pertussis vaccines published in the Weekly Epidemiological Record in January
More informationHealth Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.
This information should be read in conjunction with Immunisation Guidelines for Ireland available at http://bit.ly/niacguidelines Summary of Product Characteristics for MMR vaccines available at www.hpra.ie
More informationINFANRIX HEXA QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX HEXA Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationDiphtheria, Tetanus, and Pertussis. DTaP/DT and Tdap/Td Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Diphtheria, Tetanus, and Pertussis DTaP/DT and Tdap/Td Vaccines Jean C. Smith, MD, MPH Medical Officer
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component)
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
More informationImmunisation schedule Victoria
Infants and children July 2018 Birth H-B-Vax-II Paediatric or Paediatric 2 months (from 6 weeks) and 4 months Diphtheria-tetanus-pertussis, poliomyelitis-hepatitis B- Haemophilus influenzae type b Anterolateral
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationSummary of Key Points
Summary of Key Points WHO Position Paper on Vaccines against Pertussis September 2015 1 Background l Pertussis (whooping cough), caused by the bacterium Bordetella pertussis, was one of the most common
More informationInfanrix IPV. Copyright , MIMS Australia Page 1 of 6
Infanrix IPV MIMS Abbreviated Prescribing Information Diphtheria toxoid; pertussis vaccine; poliomyelitis vaccine; tetanus toxoid GlaxoSmithKline Australia Section: 10(a) Vaccines - Immunology Use in pregnancy:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Infanrix-IPV+Hib 1 SPC Vial + Vial 1. NAME OF THE MEDICINAL PRODUCT INFANRIX-IPV+Hib powder and suspension for suspension for injection Diphtheria, tetanus, pertussis
More informationThe National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.
The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office : Dates vaccines introduced into the Irish immunisation schedule Vaccine 1937-1999 Date introduced
More informationfor the New Zealand National Immunisation Schedule: Tetanus Auckland UniServices Limited A wholly owned company of The University of Auckland
2012 Antigen Review for the New Zealand National Immunisation Schedule: Tetanus Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand Ministry of Health
More informationVARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated
VARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated NAME OF THE MEDICINE VARILRIX is a live virus vaccine for immunisation against varicella. DESCRIPTION VARILRIX is a lyophilised preparation
More informationImmunization Update Richard M. Lampe M.D.
Immunization Update 2012 Richard M. Lampe M.D. Immunization Update List the Vaccines recommended for Health Care Personnel Explain why Health Care Personnel are at risk Recognize the importance of these
More informationTEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN
TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN Richard Smithson Neil Irvine Maureen McCartney Consultant Health Protection October 2012 Pertussis/whooping cough The disease Whooping Cough
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME VARILRIX (human albumin-free) live attenuated varicella vaccine Each dose of the reconstituted vaccine contains not less than 10 3.3 plaque-forming units (PFU) of
More informationCVU: What s new? 2 nd December 2013
CVU: What s new? 2 nd December 2013 Dr Margie Danchin Paediatrician, Department of General Medicine, RCH Senior Research Fellow, MCRI Senior Fellow, Department of Paediatrics, The University of Melbourne
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationPost-Transplant Vaccination and Re-Immunisation Procedure
Post-Transplant Vaccination and Re-Immunisation Procedure Table of Contents Purpose... 1 Scope/Audience... 1 Associated documents and forms... 1 Definitions... 2 Background... 2 Vaccination Recommendations...
More informationANNEX I ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria, tetanus, acellular pertussis, hepatitis
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationGuidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT)
Guidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Version 2.0 Approved by Haem / Onc Senior Clinical Management
More informationHepatitis B in Travellers
Hepatitis B in Travellers Please find product Prescribing Information at the end of this presentation Hepatitis B A serious blood-borne liver infection, which can cause both acute and chronic disease 1,2
More informationADT Booster Data Sheet
1. PRODUCT NAME ADT Booster. Diphtheria and Tetanus Vaccine (adsorbed) for revaccination. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ADT Booster is a suspension for intramuscular injection, containing
More informationPriorix TM Measles, mumps and rubella vaccine (live, attenuated)
Priorix TM Measles, mumps and rubella vaccine (live, attenuated) QUALITATIVE AND QUANTITATIVE COMPOSITION Priorix is a lyophilised mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived
More informationADT Booster Product Information
NAME OF THE MEDICINE ADT Booster. Diphtheria and Tetanus Vaccine (adsorbed) for revaccination. DESCRIPTION ADT Booster is a suspension for intramuscular injection, containing aluminium-hydroxide-adsorbed
More informationHIGH RISK IMMUNISATION
Overview HIGH RISK IMMUNISATION Dr. F Shaun Hosein Advanced Trainee, Public Health Medicine Sunshine Coast Public Health Unit Lecturer, University of Queensland Clinical Writer PHN Immunology Responses
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationIMMUNISATION OF CHILDREN DURING and AFTER CANCER THERAPY
NATIONAL GUIDELINES PAEDIATRIC ONCOLOGY AND HAEMATOLOGY For the Care of Childhood Cancer in Specialist Child Cancer and Shared Care Centres. IMMUNISATION OF CHILDREN DURING and AFTER CANCER THERAPY Date
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationImmunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)
Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Factsheet for healthcare professionals about the neonatal selective immunisation programme for babies at risk of hepatitis B Background All babies born
More informationVARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated
VARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated NAME OF THE DRUG VARILRIX is a live virus vaccine for immunisation against varicella. DESCRIPTION VARILRIX is a lyophilised preparation of
More informationImmunizations for Health Care Workers
Immunizations for Health Care Workers Tanisha Taylor, MD, MPH Senior Medical Director Barnabas Health Corporate Care Tanisha Taylor MD, MPH Senior Medical Director Barnabas Health Corporate Care CDC Immunizations
More informationVACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE)
VACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE) Dr.T.K.SHAANTHY GUNASINGH M.D., D.G.O., FICOG PROFESSOR AND HEAD OF THE DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY PROGRAMME DIRECTOR CENTRE OF EXCELLENCE
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationPertussis Control in New Zealand How can we do better?
Pertussis Control in New Zealand How can we do better? 1 Conflict of interest In the past I have received support for vaccine work, clinical trials, presentation of papers and conference attendance from
More information